Celcuity’s (CELC) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $27.00 target price on the stock.

Separately, Needham & Company LLC boosted their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $30.17.

Celcuity Price Performance

NASDAQ CELC opened at $9.29 on Tuesday. Celcuity has a 1 year low of $8.50 and a 1 year high of $20.89. The business’s fifty day moving average is $11.14 and its two-hundred day moving average is $12.87. The stock has a market capitalization of $344.94 million, a P/E ratio of -3.56 and a beta of 0.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Celcuity (NASDAQ:CELC) last announced its earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). On average, research analysts forecast that Celcuity will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. increased its stake in Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock valued at $45,000 after buying an additional 1,132 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Celcuity during the 4th quarter valued at $50,000. The Manufacturers Life Insurance Company acquired a new position in shares of Celcuity in the fourth quarter worth $142,000. Bleakley Financial Group LLC bought a new position in shares of Celcuity in the fourth quarter worth about $146,000. Finally, Trexquant Investment LP acquired a new position in shares of Celcuity during the fourth quarter worth approximately $152,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.